Researchers created fusion proteins combining interferon alpha-2b and thymosin alpha-1, two drugs that work synergistically against hepatitis B and C, connected by flexible linker sequences. The purified fusion proteins successfully retained both the antiviral activity of interferon and the immune-boosting activity of thymosin alpha-1, providing a foundation for developing a single combined drug.
Yang, You-Feng; Yuan, Han-Ying; Liu, Nan-Song; Chen, Xiang-Ling; Gao, Bu-Yu; Lu, Hong; Li, Yu-Yang